Ignite Creation Date:
2024-05-06 @ 3:18 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04588168
Status:
RECRUITING
Last Update Posted:
2020-10-19
First Post:
2020-09-13
Brief Title:
Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
Multi-parameter Magnetic Resonance Imaging for Early Evaluation of the Efficacy of Neoadjuvant Chemotherapy With Modified GC Regimen for Urothelial Carcinoma
Status:
RECRUITING
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PurposeTo evaluate whether immediate multiparametric MRI evaluate the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancerMIBC
RationaleMultiparametric MRI may help detect the early changes of bladder cancer receiving neoadjuvant chemotherapy
RationaleMultiparametric MRI may help detect the early changes of bladder cancer receiving neoadjuvant chemotherapy
Detailed Description:
Objective
Primary To evaluate whether multiparametric MRI can determine the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancerMIBC
SecondaryTo determine whether multiparametric MRI can predict the prognosis of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer
Patients may receive neoadjuvant chemotherapy typically three 21-day courses of modified gemcitabine-cisplatinGC therapy followed by radical cystectomy and lymph node dissection
Patients with primary bladder cancer or recurrence which is confirmed by pathology of previous biopsy or TURBT undergo a multiparametric MRImpMRI at baseline to stage the primary tumor The mpMRI includes T2-weighted MRI diffusion-weighted imaging and dynamic contrast enhancement which will be given a five-point VI-RADSVesical Imaging-Reporting And Data System score by two radiologists specialized in urogenital radiology Patients considered NMIBCNon-muscle invasive bladder cancer with mpMRI will be given TURBT while patients with MIBCMuscle invasive bladder cancerwill receive radical cystectomy and lymph node dissection after three 21-day courses of modified gemcitabine-cisplatin neoadjuvant chemotherapy Patients also undergo an immediate mpMRI scan after one two and three cycles of neoadjuvant chemotherapy
Specimens from the radical cystectomy are then examined by the pathology department as standard routine
Primary To evaluate whether multiparametric MRI can determine the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancerMIBC
SecondaryTo determine whether multiparametric MRI can predict the prognosis of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer
Patients may receive neoadjuvant chemotherapy typically three 21-day courses of modified gemcitabine-cisplatinGC therapy followed by radical cystectomy and lymph node dissection
Patients with primary bladder cancer or recurrence which is confirmed by pathology of previous biopsy or TURBT undergo a multiparametric MRImpMRI at baseline to stage the primary tumor The mpMRI includes T2-weighted MRI diffusion-weighted imaging and dynamic contrast enhancement which will be given a five-point VI-RADSVesical Imaging-Reporting And Data System score by two radiologists specialized in urogenital radiology Patients considered NMIBCNon-muscle invasive bladder cancer with mpMRI will be given TURBT while patients with MIBCMuscle invasive bladder cancerwill receive radical cystectomy and lymph node dissection after three 21-day courses of modified gemcitabine-cisplatin neoadjuvant chemotherapy Patients also undergo an immediate mpMRI scan after one two and three cycles of neoadjuvant chemotherapy
Specimens from the radical cystectomy are then examined by the pathology department as standard routine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None